BioMerieux (STU:EYWN) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:EYWN BioMerieux SA STU:EYWN
69 GF Score
Price €72.10
GF Value €109.41
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:EYWN
69GF Score
BioMerieux SA STU:EYWN
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioMerieux (STU:EYWN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of €72.10 is trading 34.1% below its estimated GF Value™ of €109.41. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for STU:EYWN:

  • Interest Received:
  • GF Value™: €109.41 vs. price of €72.10 (34.1% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the STU:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
69GF Score

Get the complete analysis for STU:EYWN

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€72.10
Price
€109.41
GF Value